share_log

Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Maintains $20 Price Target

Benzinga ·  Mar 28 12:36

Chardan Capital analyst Keay Nakae maintains Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy and maintains $20 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 388

Recommended

Write a comment